Researchers analyzing plasma samples of 53 HCT recipients identified 4 proteins that when used in a biomarker panel was prognostic of developing chronic graft-versus-host disease (cGVHD). The analysis compared pooled plasma samples obtained at matched time points after HCT (median, 103 days) from 35 patients with cGVHD and 18 without cGVHD, in addition to two independent verification cohorts (n=391). Increased levels of the four biomarkers in the panel (ST2, CXCL9, matrix metalloproteinase 3, and osteopontin) were significantly correlated with cGVHD diagnosis, cGVHD severity, and non-relapse mortality in 178 patients with cGVHD receiving corticosteroid treatment at the time of sampling and 33 patients without cGVHD. The researchers concluded that the biomarker panel measured at diagnosis or day +100 post-transplant may allow patient stratification according to risk of cGVHD.
Biomarker Panel Can Predict Risk of Chronic GVHD